Hepatotoxicity of hypolipidemic drugs

Clinics in Liver Disease

Volumn 7, Issue 2, 2003, Pages 415-433

  Parra, Javier L ^a   Reddy, K Rajender ^b  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CHLOROQUINE; CHLORZOXAZONE; COLESEVELAM; COLESTIPOL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; METFORMIN; MEVINOLIN; NICOTINIC ACID; POLICOSANOL; PRAVASTATIN; SIMVASTATIN; TROGLITAZONE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DRUG ALCOHOL INTERACTION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EOSINOPHILIA; FATIGUE; FATTY LIVER; FEVER; FLATULENCE; FLUSHING; HEADACHE; HUMAN; IMPOTENCE; LIPID METABOLISM; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; METABOLIC ACIDOSIS; MYALGIA; MYOPATHY; NAUSEA; PAIN; PATHOGENESIS; PATIENT MONITORING; POSTMARKETING SURVEILLANCE; REVIEW; RHABDOMYOLYSIS; TOXIC HEPATITIS;

EID: 0037709132     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00024-2     Document Type: Review

References (89)

1. Cardiovascular Diseases Prevention and Control. World Health Report, 2002.
2. World Health Organization website available at: www.who.int/ncd/cvd. Accessed December, 2002.
3. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Vital Health Statistics [1] 1994;32:20-2.
4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-9.
5. Lipids Research Clinic Program. The lipid research clinics coronary primary prevention trial results. I. Reduction incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:351-64.
6. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
7. The Long-term intervention with Pravastatin in ischemic disease (LIPID) study group prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1998;333:1301-7.
8. Wilson PWF. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994;7:7s-12s.
9. Grimm Jr RH. The multiple risk factor intervention trial in the US. A summary of results at four years in special intervention and usual care men. Prev Med 1983;12:185-90.
10. Shepherd J. The west of Scotland coronary prevention study: a trial of cholesterol reduction in Scottish men. Am J Cardiol 1995;76:113C-7C.
11. Lennemas H. Pharmakodynamics and pharmakokinetics of the HMG CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet 1997;32:403-25.
12. White CM. A review of HMG CoA reductase inhibitors. US Pharmacist 1998;23:HS19-30.
13. Gerson RJ, MacDonald JS. Animal safety and toxicology of simvastatin and related hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Med 1989;87:S28-38.
14. Slater EE, MacDonald JS. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs 1988;36(Suppl 3):72-82.
15. Muldoon MF, Manuck SM, Matthews KM. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990;301:309-14.
16. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992;304:431-4.
17. Kritchevsky SB, Kritchevsky D. Serum cholesterol and cancer risk: an epidemiologic perspective. Annu Rev Nutr 1992;12:391-416.
18. Muldoon MF, Manuck SB, Mendelsohn AB, et al. Cholesterol reduction and non-illness mortality: meta-analysis of randomized clinical trials. BMJ 2001 Jan 6;322:(7277):11-5.
19. White CM, et al. A review of HMG-CoA reductase inhibitors. US Pharmacist 1998;23:HS19-30.
20. Hamelin B, et al. Hydrophilicity/Lypophilicity: relevance of the pharmacology and clinical effects of HMG CoA reductase inhibitors. Trends Pharmacol Sci 1998;19:26-37.
21. Bottorf M, Hansten P. Long term safety of hepatic hydroxymethyl glutaryl coenzyme A Reductase Inhibitors. Arch Intern Med Aug 14/28, 2000;160:2273-80.
22. Azie NE, Brater DC, et al. Interaction of Diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998;64:369-77.
23. Kantola T, Kivist KT, et al. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998;64:58-65.
24. Neuvonen PJ, Jalava KM, et al. Itracoonazole drastically increases the concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
25. Neuvonen PJ, Kantola T, et al. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41.
26. Physician's Desk Reference. 53rd edition. Montvale NJ: Medical Economics Company, Inc.; 1999.
27. Tolman KG. defining patient risks from expanded preventive therapies. Am J Cardiol 2000;85:E15-9.
28. lllingworth DR. An overview of lipid-lowering drugs. Drugs 1988;36(Suppl 3):63-71.
29. Shek A, et al. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17.
30. Walker JF. HMG-CoA reductase inhibitors: current clinical experience. Drugs 1988;36(Suppl 3):83-6.
31. Boccuzi SJ, Bocanegra TS, Walker JF, et al. Long-term safety and efficacy profile of simvastatin. Am Jour Cardiol 1991;68:1127-31.
32. Pedersen TR, Berg K, Cook TJ, et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Int Med 1996;156:2085-92.
33. Ballare M, Campanini M, Airoldi G, et al. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors. Minerva Gastroenterol Dietol 1992;38:41-4.
34. Davignon J, Montigny M, Dufour R. HMG-CoA reductase inhibitors: a look back and a look ahead. Can J Cardiol 1992;8:843-64.
35. Caldwell SH, Hespenheide EE, von Borstel RW. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci 2001;46:376-8.
36. Heuer T, Gerads H, Pauw M, Gabbert HE, Reis HE. Toxic liver damage caused by HMG-CoA reductase inhibitor. Med Klin 2000;95:642-4.
37. Bielecki JW, Schraner C, Briner V, Kuhn M. Rhabdomyolysis and cholestatic hepatitis under treatment with simvastatin and chlorzoxazone CYP2E1 substrate. Schweiz Med Wochenschr [abstract] 1999;129:514-8.
38. Koomstra JJ, Ottervanger JP, Fehmers MC, Stricker BH. Clinically manifest liver lesions during use of simvastatin. Ned Tijdschr Geneeskd [abstract] 1996;140:846-8.
39. Mantell G, Burke MT, Staqqers J. Extended clinical safety profile of lovastatin. Am J Cardiol 1990;66:B11-5.
40. Tobert JA, Shear CL, Chremos AN, Mantell GE. Clinical experience with lovastatin. Am J Cardiol 1990;65:F23-6.
41. Tolman K. The Liver and Lovastatin. Am J Cardiol 2002;89:1374-80.
42. Bruguera M, Jova P, Rodes J. Hepatitis associated with treatment with lovastatin. Presentation of 2 cases. Gastroenterol Hepatol 1998;21:127-8.
43. Huchzermeyer H, Munzenmaier R. Lovastatin-induced acute cholestatic hepatitis. Dtsch Med Wochenschr 1995;120:252-6.
44. Grimbert S, Pessayre D, Degott C, Benhamou JP. Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin. Dig Dis Sci 1994;39:2032-3.
45. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998;158:577-84.
46. Jimenez-Alonso J, Osorio JM, Gutierrez-Cabello F, et al. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Arch Intern Med 1999;159:1811-2.
47. Pfeffer M, Keech A, Sacks F, Cobbe S. Safety and Tolerability of Pravastatin in Long-Term Clinical Trials. Prospective Pravastatin Pooling Project Circulation 2002;105:2341-6.
48. Hartleb M, Rymarczyk G, Januszewski K. Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol 1999;94:1388-90.
49. Deslypere JP. Clinical implications of the biopharmaceutical properties of fluvastatin. Am J Cardiol 1994;73:D12-7.
50. Talk Paper August FDA. Available at: www.fda.gov/bbs/topics/ANSWERS/2001/ANS01095.html. Accessed December, 2002.
51. International task force for prevention of coronary heart disease. Scientific background and new clinical guidelines: recommendations of the European Atherosclerosis Society. Nutr Metab Cardiovasc Dis 1992;2:113-56.
52. Adult Treatment Panel II. Summary of the second report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 1993;269:3015-23.
53. Frick MH, Elo O, et al. Helsinki heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
54. Huttunen J, Manninen V, et al. The Helsinki heart study: central findings and clinical implications. Ann Med 1991;23:155-9.
55. Huttunen J, Heinonen O, et al. The Helsinki heart study: an 8.5-year safety and mortality follow-up. J Intern Med 1994;235:31-9.
56. Ericsson C-G, Hamsten A, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53.
57. Frick MH, Syvanne M, et al. Prevention of the angiographic progression of coronary and veingraft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997;96:2137-43.
58. Blane GF. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med 1987;83:26-36.
59. Blane GF. Review of European clinical experience with fenofibrate. Cardiology 1989;76(Suppl 1):1-13.
60. Staels B, Dallongeville J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93.
61. Guay DR. Micronized fenofibrate: a new fibric acid hypolipidemic agent. Ann Pharmacother 1999;33:1083-103.
62. Ganne-Carrie N, de Leusse A, Guettier C, et al. Autoimmune hepatitis induced by fibrates. Gastroenterol Clin Biol 1998;22:525-9.
63. Lelouch S, Pelletier G, Sinico M. Fenofibrate-induced acute hepatitis with pseudo-cholangitis. Gastroenterol Clin Biol 1992;16:597-9.
64. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992;92:77-81.
65. Henkin Y, Oberman A, Hurst DC, Segrest JP. Niacin revisited: clinical observations on an important but underutilized drug. Am J Med 1991;91:239-46.
66. Kristensen T, Olcott EW. Effects of niacin therapy that simulate neoplasia: hepatic steatosis with concurrent hepatic dysfunction. J Comput Assist Tomogr 1999;23:314-7.
67. Lawrence SP. Transient focal hepatic defects related to sustained-release niacin. J Clin Gastroenterol 1993;16:234-6.
68. Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release niacin. Am J Med 1992;93:102-4.
69. Ferenchick G, Rovner D. Hepatitis and hematemesis complicating nicotinic acid use. Am J Med Sci 1989;298:191-3.
70. Patterson DJ, Dew EW, Gvorkey F, Graham DY. Niacin hepatitis. South Med J 1983;76:239-41.
71. Etchason JA, Miller TD, Squires RW, et al. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin Proc 1991;66:23-8.
72. Henkon Y, Johnson KC, Segrest JP. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. JAMA 1990;264:241-3.
73. Brown WV. Niacin for lipid disorders. Indications, effectiveness, and safety. Postgrad Med 1995;98:185-93.
74. Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol 1994;73:D25-9.
75. Patel SD, Taylor HC. Intrahepatic cholestasis during nicotinic acid therapy. Cleve Clin J Med 1994;61:70-82.
76. Schwab RA, Bachhuber BH. Delirium and lactic acidosis caused by ethanol and niacin coingestion. Am J Emerg Med 1991;9:363-5.
77. Clementz GL, Holmes AW. Nicotinic acid-induced fulminant hepatic failure. J Clin Gastroenterol 1987;9:582-4.
78. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-900.
79. Shepherd J, Packard CJ, Morgan HG, Third JL, Stewart JM, Lawrie TD. The effects of cholestyramine on high-density lipoprotein metabolism. Atherosclerosis 1979;33:433-44.
80. Sirmans SM, Beck JK, Bahn HL, Freeman DA. Colestipol-induced hepatotoxicity. Ann Pharmacother 2001;21:513-6.
81. Davidson MH, Dicklin MR, Maki KC, Kleinpell RM. Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. Expert Opin Investig Drugs 2000;9:2663-71.
82. Dunstan DW, Mori TA, Puddey IB, et al. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM: A randomized controlled study. Diabetes Care 1997;20:913-21.
83. Mori TA, Watts GF, Burke V, et al. Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men. Circulation 2000;102:1264-9.
84. Minihane AM, Khan S, Leigh-Firbank EC, et al. ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler Thromb Vasc Biol 2000;20:1990-7.
85. Dunstan DW, Mori TA, Puddey IB, et al. The independent and combined effects of aerobic exercise and dietary fish intake on serum lipids and glycemic control in NIDDM: a randomized controlled study. Diabetes Care 1997;20:913-21.
86. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002;143:356-65.
87. Isaacsohn JL. Garlic powder and plasma lipids and lipoproteins: a multicenter, randomized, placebo-controlled trial. Arch Intern Med 1998;158:1189-94.
88. McQueen MJ. Cholestatic jaundice associated with lovastatin (Mevacor) therapy. Can Med Assoc J 1990;142:841-2.
89. Lovastatin and cholestasis. Canadian Medical Association Journal 1993;148(3):374.